We recently published a list of 10 Cheap NYSE Stocks To Invest In Now. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other cheap NYSE stocks to invest in now.
The stock market appears poised for another year of impressive returns, likely extending into 2025. However, concerns about high valuations persist. To gain insight into this, Aswath Damodaran, professor of finance at NYU Stern School of Business, recently joined CNBC’s ‘Closing Bell’ on December 14. Damodaran recognized that it’s tough to keep up after two years of returns over 25%. He mentioned that if the market stays stable until the end of the year, it would be similar to the high points seen in the 1950s and mid-1970s. However, he was doubtful about being able to keep this strong performance going, as it’s challenging to continue rising after such big gains.
When asked if the market is overvalued, Damodaran said that while prices are high, they haven’t reached the level of a bubble yet. He compared the current situation to the late 1990s but clarified that he doesn’t plan to sell all his investments. Instead, he is hesitant to invest cash right away because staying in cash might mean losing out on potential gains. He also mentioned that while there may be limited growth in price-to-earnings ratios in 2025, there could still be good returns due to better-than-expected earnings growth from new government policies. Damodaran believes that a return of 8% to 10% would be satisfactory for him, as he prioritizes preserving wealth over aiming for very high returns.
The US stock market currently presents a mixed valuation picture. According to Morningstar, Large growth stocks have experienced significant price appreciation. However, their current valuations may not fully reflect the inherent risks associated with high growth expectations and potential competition. Consumer defensive stocks tend to be less volatile during economic downturns, but the current valuations may be inflated due to a perceived safe-haven status. Utilities may be currently overvalued relative to their historical performance and future earnings potential as interest rates rise. The industrial sector may be overvalued due to concerns about potential economic slowdowns and rising input costs, although some sub-sectors may offer value.
Conversely, the communication services sector may present attractive opportunities for investors. While facing challenges such as increased competition and regulatory scrutiny, certain companies within this sector may be undervalued relative to their long-term growth prospects. The energy sector has experienced significant volatility in recent years. However, with increasing global energy demand and ongoing geopolitical uncertainties, certain segments of the energy sector may be undervalued at current prices.
Markets are constantly evolving, influenced by various factors such as economic growth, interest rates, and geopolitical events. Damodaran’s insights reflect a cautious view of market prospects heading into 2025, emphasizing careful investment strategies amid high valuations.
Methodology
We sifted through the Finviz stock screener to compile a list of the top NYSE-listed stocks. We then selected the 10 stocks with a forward P/E ratio under 15 that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q3 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A close-up of a person’s hand holding a bottle of pharmaceuticals.
Merck & Co. Inc. (NYSE:MRK)
Current Forward P/E as of December 16: 10.53
Number of Hedge Fund Holders: 86
Merck & Co. Inc. (NYSE:MRK) is a global pharmaceutical leader dedicated to the discovery, development, and commercialization of innovative medicines, vaccines, and animal health products. It focuses on addressing serious health challenges, including cancer, cardiovascular diseases, and infectious diseases.
The company has achieved a nearly threefold increase in its Phase 3 pipeline over the past 3 years, now exceeding 20 unique assets. It anticipates launching numerous new products in the next 5 years, potentially surpassing the number launched in the past decade. This is fueled by internal research efforts and value-creating business development transactions such as the recent acquisition of Curon, a clinical-stage biopharmaceutical company.
Merck & Co. Inc. (NYSE:MRK) has made clinical progress across different therapeutic areas. A key example of this is KEYTRUDA, a type of immunotherapy for cancer. Its sales grew 21% year-over-year to $7.4 billion in Q3 2024. Ongoing clinical successes and expanding indications for KEYTRUDA solidify its position as a key driver of the company’s growth.
Oakmark Equity and Income Fund stated the following regarding Merck & Co., Inc. (NYSE:MRK) in its Q3 2024 investor letter:
“Merck & Co., Inc. (NYSE:MRK) is a global pharmaceutical firm with leading oncology, vaccine and animal health franchises. Premier products in Merck’s portfolio include Keytruda, Gardasil, Winrevair and Bravecto. Outsized contributor Keytruda is an immuno-oncology drug that treats several cancers and tumors. Keytruda is an astounding clinical and commercial success that is on track to become one of the best-selling prescription drugs to date. Investor angst surrounding Keytruda’s pending U.S. patent expiration in 2028 presented a chance to buy shares at a discounted valuation. We believe opportunities to extend Keytruda’s duration through life cycle management are underappreciated. More importantly, discounted cash flows from products already on market cover today’s entire stock price, meaning there is minimal value ascribed to a promising pipeline with strong sales potential. We believe Merck is led by a capable management team that looks to reinvest these cash flows in an accretive manner.”
Overall, MRK ranks 5th on our list of cheap NYSE stocks to invest in now. While we acknowledge the growth potential of MRK, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.
